ATE453723T1 - Psoriasin-expression durch brustepithelzellen - Google Patents

Psoriasin-expression durch brustepithelzellen

Info

Publication number
ATE453723T1
ATE453723T1 AT02806283T AT02806283T ATE453723T1 AT E453723 T1 ATE453723 T1 AT E453723T1 AT 02806283 T AT02806283 T AT 02806283T AT 02806283 T AT02806283 T AT 02806283T AT E453723 T1 ATE453723 T1 AT E453723T1
Authority
AT
Austria
Prior art keywords
dcis
high grade
hid
risk
epithelial cells
Prior art date
Application number
AT02806283T
Other languages
English (en)
Inventor
Kornelia Polyak
Charlotta Enerbaeck
Original Assignee
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Inst Inc filed Critical Dana Farber Cancer Inst Inc
Application granted granted Critical
Publication of ATE453723T1 publication Critical patent/ATE453723T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT02806283T 2001-12-31 2002-12-30 Psoriasin-expression durch brustepithelzellen ATE453723T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34574001P 2001-12-31 2001-12-31
PCT/US2002/041795 WO2003057159A2 (en) 2001-12-31 2002-12-30 Psoriasin expression by breast epithelial cells

Publications (1)

Publication Number Publication Date
ATE453723T1 true ATE453723T1 (de) 2010-01-15

Family

ID=23356293

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02806283T ATE453723T1 (de) 2001-12-31 2002-12-30 Psoriasin-expression durch brustepithelzellen

Country Status (9)

Country Link
US (2) US7465553B2 (de)
EP (1) EP1470239B1 (de)
JP (1) JP2005526233A (de)
AT (1) ATE453723T1 (de)
AU (1) AU2002367317A1 (de)
CA (1) CA2472163C (de)
DE (1) DE60234958D1 (de)
ES (1) ES2338774T3 (de)
WO (1) WO2003057159A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030198972A1 (en) 2001-12-21 2003-10-23 Erlander Mark G. Grading of breast cancer
US9856533B2 (en) * 2003-09-19 2018-01-02 Biotheranostics, Inc. Predicting breast cancer treatment outcome
GB0412620D0 (en) * 2004-06-05 2004-07-07 Univ Belfast BRCA1 markers
US8379960B2 (en) * 2009-03-30 2013-02-19 Ge Healthcare Bio-Sciences Corp. System and method for distinguishing between biological materials
WO2010118324A2 (en) 2009-04-09 2010-10-14 Nuclea Biotechnologies, LLC Antibodies against fatty acid synthase
WO2011031517A1 (en) 2009-08-27 2011-03-17 Nuclea Biotechnologies, LLC Method and assay for determining fas expression
EP2648762B1 (de) 2010-12-09 2018-02-21 Biotheranostics, Inc. Brustkrebs-nachbehandlungsprognose
CN105873950A (zh) * 2013-04-09 2016-08-17 莱克尔生物医学有限公司 用于治疗和诊断癌症的抗s100a7抗体
MX2018005867A (es) 2015-11-13 2018-09-21 Biotheranostics Inc Integracion de las caracteristicas tumorales con el indice de cancer de mama.
US11360092B2 (en) 2016-08-05 2022-06-14 The Research Foundation For The State University Of New York Keratin 17 as a biomarker for bladder cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3382317D1 (de) 1982-03-15 1991-07-25 Schering Corp Hybride dns, damit hergestellte bindungszusammensetzung und verfahren dafuer.
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (de) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimäre Rezeptoren durch Verbindung und Expression von DNS
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
CA2349593A1 (en) * 1998-11-05 2000-05-11 The Regents Of The University Of Michigan S100 proteins and autoantibodies as serum markers for cancer
EP1159619A2 (de) * 1999-03-15 2001-12-05 EOS Biotechnology, Inc. Verfahren zur diagnose und zum behandeln von brustkrebs
CA2410056A1 (en) 2000-05-17 2001-11-22 Oregon Health Science University Induction of apoptosis and cell growth inhibition by protein 4.33
IT1395574B1 (it) 2009-09-14 2012-10-16 Guala Dispensing Spa Dispositivo di erogazione

Also Published As

Publication number Publication date
AU2002367317A1 (en) 2003-07-24
DE60234958D1 (de) 2010-02-11
EP1470239A4 (de) 2006-08-23
CA2472163A1 (en) 2003-07-17
US20030138833A1 (en) 2003-07-24
WO2003057159A2 (en) 2003-07-17
JP2005526233A (ja) 2005-09-02
ES2338774T3 (es) 2010-05-12
EP1470239A2 (de) 2004-10-27
EP1470239B1 (de) 2009-12-30
AU2002367317A8 (en) 2003-07-24
WO2003057159A9 (en) 2004-06-03
CA2472163C (en) 2012-12-18
WO2003057159A3 (en) 2003-12-18
US20090104618A1 (en) 2009-04-23
US7776541B2 (en) 2010-08-17
US7465553B2 (en) 2008-12-16

Similar Documents

Publication Publication Date Title
Xing et al. Neuroendocrine cells in human prostate over‐express the anti‐apoptosis protein survivin
Forootan et al. Prognostic significance of osteopontin expression in human prostate cancer
Li et al. Matrix metalloproteinase-2 and-9 expression correlated with angiogenesis in human adenomyosis
Zagars Prostate specific antigen as an outcome variable for T1 and T2 prostate cancer treated by radiation therapy
MXPA05001766A (es) Uso de proteina quinasa n beta.
WO2002018544A3 (en) Method and reagents for treatment of skin disorders by modulating the notch pathway
ATE453723T1 (de) Psoriasin-expression durch brustepithelzellen
DE60137264D1 (de) Monoklonale antikörper und zelloberflächenantigene zum nachweis und zur behandlung von kleinzelligem lungenkrebs (sclc)
HK1070921A1 (en) Method for determining the expression level of glutathione-s-transferase pi
EP1404365A4 (de) Verfahren und zusammensetzungen zur hemmung, prävention oder verringerung des tumorzellwachstums bei patienten, die gegen die antineoplastischen wirkungen einer antiöstrogen-therapie resistent sind
Katono et al. Clinicopathological significance of S100A10 expression in lung adenocarcinomas
WO2007015113A3 (en) New protein isoforms of the pif-family and uses thereof
WO2004031414A3 (en) Method for diagnosing prostate cancer
ATE352311T1 (de) Verwendung von brustkrebs membranproteine für behandlung, prophylaxe und diagnose von brustkrebs
Chuang et al. Immunohistochemical expression of RANKL, RANK, and OPG in human oral squamous cell carcinoma
Huang et al. Serum and tissue expression of gelatinase and Twist in breast cancer.
DE50313393D1 (de) Verfahren zur diagnose von entzündungserkrankungen und infektionen mittels bestimmung von lasp-1/ lap-1
Avirović et al. Osteopontin expression is an independent factor for poor survival in oral squamous cell carcinoma: a computer‐assisted analysis on TMA sections
DE60113968D1 (de) Diagnose von brustkrebs unter verwendung von bcmp-7 als marker
Doganavsargil et al. A comparison of p21 and p27 immunoexpression in benign glands, prostatic intraepithelial neoplasia and prostate adenocarcinoma
Matsuyama et al. Gallbladder cancers rarely overexpress HER-2/neu, demonstrated by Hercep test
Mahmood et al. Matrix metalloproteinases MMP2 and MMP9 expression in stages II-III breast cancer in Iraqi women
Šundov et al. Immunohistochemically detected high expression of matrix metalloproteinase-2 as predictor of poor prognosis in Duke’s B colon cancer
Linder et al. Evaluation of tissue and serum VEGF in patients with head and neck carcinoma
DE60032333D1 (de) Zusammensetzungen und verfahren zur intraductalen gentherapie

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties